Skip to main content
Clinical Trials/NCT05747599
NCT05747599
Completed
Not Applicable

Adapting and Testing a Behavioural Intervention to Prevent FASD and Adverse Infant Outcomes

RTI International1 site in 1 country48 target enrollmentApril 1, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Maternal Behavior
Sponsor
RTI International
Enrollment
48
Locations
1
Primary Endpoint
Number of Participants With Negative Urinalysis for Cannabis Metabolite (THC)
Status
Completed
Last Updated
last year

Overview

Brief Summary

South Africa (SA) has a long history of social and health disparities, resulting in the world's highest rate of fetal alcohol spectrum disorder (FASD; 111.1 per 1,000), where lifelong negative cognitive and physical effects result from prenatal alcohol exposure. FASD is completely preventable if women do not drink during pregnancy. Prenatal alcohol use frequently co-occurs with other substance use, especially tobacco and cannabis. The adverse effect on birth outcomes by alcohol and tobacco use together is worse than either substance alone. Recent evidence from animal models shows that prenatal exposure to both cannabinoids and alcohol potentiate the likelihood of alcohol-induced birth defects.

Data from Cape Metropole, SA, showed that all women who reported prenatal alcohol use also tested positive for tobacco use, with 25% also reporting cannabis use. Alcohol use while breastfeeding also occurs at a relatively high rate in SA. Despite tremendous health benefits from breastfeeding,maternal alcohol use while breastfeeding significantly compromises infant development. Contingency management (CM) has been efficacious in reducing prenatal cocaine, alcohol, and tobacco use in the United States (U.S.). The Women's Health CoOp (WHC) is an evidence-based brief intervention addressing women-focused syndemic issues and resulting disparities associated with substance and alcohol use. These evidence-based interventions need to be combined and adapted for addressing maternal polysubstance use and associated health and behavioral issues during pregnancy and lactation in SA. The Specific Aims are as follows: (1) R61 Aim 1- Conduct formative qualitative research with women who are pregnant or breastfeeding with a recent history of polysubstance use, clinic and community stakeholders, and an established Community Collaborative Board. (2) R61 Aim 2-Test feasibility, acceptability, and appropriateness of the adapted intervention with 48 women (24 pregnant and 24 breastfeeding) in Cape Metropole, SA. (3) R33 Aim 1-Examine the effectiveness of the adapted intervention (i.e., CM and text-based support with WHC educational components) in a 2-group randomized controlled trial with 184 women who are pregnant and follow up during pregnancy and 3 months postpartum. (4) R33 Aim 2-Examine the impact on gestational, birth, and infant outcomes. (5) R33 Aim 3-Track cost and conduct preliminary cost-effectiveness analyses.

Registry
clinicaltrials.gov
Start Date
April 1, 2023
End Date
October 31, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Yukiko Washio

Principal Investigator

RTI International

Eligibility Criteria

Inclusion Criteria

  • For key informant interviews in R61 To be eligible, women must (1) 18 or older, (2) be pregnant or breastfeeding with less than 12 months postpartum, (3) report alcohol use , (4) report tobacco or cannabis use
  • For testing in R61,
  • be in the second trimester of pregnancy or breastfeeding with less than 3 months postpartum,
  • test positive in alcohol use by urinalysis (i.e., EtG),
  • test positive in tobacco or cannabis use by urinalysis (i.e., cotinine and THC),
  • be over 18 years old
  • have a negative HIV test,
  • not be eligible for PrEP
  • plan to complete antenatal care at the current clinic and remain in the area for at least 3 months
  • own a cell phone to receive text messages.

Exclusion Criteria

  • (1) women who report serious medical problems threatening their current pregnancy or current suicidal thoughts or attempts in the past month. These women will be provided necessary referrals.
  • (2) Women who participated in interviews.

Outcomes

Primary Outcomes

Number of Participants With Negative Urinalysis for Cannabis Metabolite (THC)

Time Frame: 3-month postpartum

Biochemical verification of recent cannabis use in urine samples. A cannabis metabolite (THC) will be measured in urine samples. The metabolite can be detected up to 28 days after heavy use. The dipstick testing will have ≥50 ng/mL as a cutoff value.

Number of Days in the Past 7-day Tobacco Use

Time Frame: 3-month postpartum

The number of days in the past 7 days that participants used tobacco.

Number of Days in the Past 7-day Alcohol Use

Time Frame: 3-month postpartum

The number of days in the past 7 days that participants used alcohol.

Number of Participants With Negative Urinalysis for Alcohol Metabolite (EtG)

Time Frame: 3-month postpartum

An alcohol metabolite (EtG) will be measured in urine samples. EtG can be detected in the urine up to 5 days after heavy drinking and up to 2 days after light drinking. The dipstick testing will have ≥300 ng/mL as a cutoff value.

Number of Participants With Negative Urinalysis for Nicotine Metabolite (Cotinine)

Time Frame: 3-month postpartum

Biochemical verification of recent tobacco use in urine samples. A tobacco metabolite (cotinine) will be measured in urine samples. The metabolite can be detected up to 3-4 days after use. The dipstick testing will have ≥200 ng/mL as a cutoff value.

Number of Days in the Past 7-day Cannabis Use

Time Frame: 3-month postpartum

The number of days in the past 7 days that participants used cannabis.

Secondary Outcomes

  • Number of Days in the Past 7-day Tobacco Use While Breastfeeding(3-month postpartum)
  • Number of Days in the Past 7-day Cannabis Use While Breastfeeding(3-month postpartum)
  • Number of Days in the Past 7-day Alcohol Use While Breastfeeding(3-month postpartum)

Study Sites (1)

Loading locations...

Similar Trials